Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03660930 · ClinicalTrials.gov registry record · Phase 1
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03660930 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 19 participants.
The verdict
NCT03660930, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of nab-sirolimus and how well it works when given together with pazopanib hydrochloride in treating participants with nonadipocytic soft tissue sarcomas that has spread to other places in the body (advanced). Nab-sirolimus and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Sirolimus Albumin-bound Nanoparticles
- DRUG Pazopanib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03660930
The ClinicalTrials.gov registry entry for NCT03660930 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus Albumin-bound Nanoparticles is the first listed.
NCT03660930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03660930 about?
NCT03660930 is a clinical study titled "Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas". This phase I/II trial studies the side effects and best dose of nab-sirolimus and how well it works when given together with pazopanib hydrochloride in treating participants with nonadipocytic soft tissue sarcomas that has spread to other places in the body (advanced). Nab-sirolimus and pazopanib hy...
What is the current status of trial NCT03660930?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-04-01. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT03660930?
The interventions under investigation include: Sirolimus Albumin-bound Nanoparticles (DRUG), Pazopanib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03660930?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.